Alongside long-term data showing patients were still benefiting from Zolgensma, Novartis said a trial patient's death wasn't related to the therapy.
New real-world data from Lilly and BI show their SGLT2 med Jardiance topped GLP-1s at preventing heart failure hospitalization.
Following its headline-grabbing presentation at ESC, AZ is out with more data that support Farxiga use in nondiabetic heart failure patients.
The Chinese approval in January opened up a large market with an estimated 14 million irritable bowel syndrome with constipation patients to Linzess.
Talk about making pharma history. Merck's Keytruda has racked up yet another first-of-its-kind approval, this time in a combo with Eisai’s Lenvima.
Novo Nordisk’s Ozempic is off to a blazing start, and the company just threw more fuel on the fire with a pair of trial wins.
Sanofi joins the digital therapeutics market Tuesday with a proposed app to improve mental health in patients with multiple sclerosis.
Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.
AstraZeneca is touting SGLT2 med Farxiga’s cardiovascular outcomes win as a game changer for the market. Turns out the FDA likes those results, too.
AbbVie isn't likely to give up its top spot soon when it comes to pharma TV ad spending, and now there's a repeat spender in the No. 2 spot, too.
